Harbin Gloria Pharmaceuticals Co., Ltd

Shenzhen Stock Exchange 002437.SZ

Harbin Gloria Pharmaceuticals Co., Ltd Gross Profit for the year ending December 31, 2023: USD 215.52 M

Harbin Gloria Pharmaceuticals Co., Ltd Gross Profit is USD 215.52 M for the year ending December 31, 2023, a -37.74% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Harbin Gloria Pharmaceuticals Co., Ltd Gross Profit for the year ending December 31, 2022 was USD 346.15 M, a -5.02% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Gross Profit for the year ending December 31, 2021 was USD 364.43 M, a 5.17% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Gross Profit for the year ending December 31, 2020 was USD 346.53 M, a -34.90% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Gross Profit for the year ending December 31, 2019 was USD 532.34 M, a -10.40% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Shenzhen Stock Exchange: 002437.SZ

Harbin Gloria Pharmaceuticals Co., Ltd

CEO	Mr. Leifeng Guo
IPO Date	Oct. 27, 2011
Location	China
Headquarters	No. 29, Beijing Road
Employees	3,085
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Personal Care

Description

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.

Key trends

Past 5 years